Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer

Keyphrases

• Etoposide 100%
• Pharmacologic 100%
• Patients with Advanced Cancer 100%
• Steady State 50%
• Dose Level 33%
• Performance Status 33%
• Neutrophils 16%
• Plasma Parameters 16%
• Inter-patient Variability 16%
• Tolerability 16%
• Clinical Practice 16%
• Neutropenia 16%
• Pharmacokinetics-pharmacodynamics (PK-PD) 16%
• Pharmacodynamics 16%
• Correlation Coefficient 16%
• Pharmacokinetic Parameters 16%
• Area under the Curve 16%
• Steady-state Value 16%
• Inter-patient 16%
• Plasma Clearance 16%
• Maximum Tolerated Dose 16%
• Pharmacodynamic Model 16%
• Phase I Study 16%
• Myelosuppression 16%
• Treatment Cycle 16%
• Prior Chemotherapy 16%
• Karnofsky Performance Status 16%
• Pharmacokinetic Variability 16%
• Relationship between Variables 16%
• First Treatment 16%
• Hematologic Variables 16%
• Hematotoxicity 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Etoposide 100%
• Advanced Cancer 100%
• Pharmacodynamics 33%
• Pharmacokinetics 33%
• Tolerability 16%
• Neutropenia 16%
• Isoprenaline 16%
• Pharmacokinetic Parameter 16%
• Maximum Tolerated Dose 16%
• Bone Marrow Suppression 16%
• Patient History of Chemotherapy 16%